The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

The Health Care Select Sector SPDR ETF (XLV) faces a pivotal inflection point heading into 2026, with the sector's relative performance dependent on two critical macro variables. Despite YTD underperformance of approximately 3% versus the S&P 500, the fund has recovered 14% over a rolling 12-month basis, signaling underlying resilience within large-cap healthcare holdings such as JNJ and ABBV. This divergence between near-term weakness and medium-term strength suggests structural rotation patterns rather than fundamental deterioration in the sector.

The article's focus on 2026 policy dynamics implies that healthcare's relative valuation and momentum depend heavily on regulatory and monetary policy frameworks. Pricing pressures on pharmaceuticals, reimbursement dynamics, and potential shifts in healthcare spending patterns tied to fiscal policy will likely serve as the two deciding factors. These variables create asymmetric risk, as policy tailwinds could accelerate sector catch-up while headwinds may extend underperformance.

XLV's correlation with broad equities appears moderately positive but decoupled from recent strength, indicating sector-specific headwinds offsetting macro bullishness. The 14% recovery over 12 months suggests institutional accumulation despite tactical weakness, pointing to conviction that mean reversion may be a 2026 narrative. Healthcare's defensive characteristics position it as potential beneficiary if growth concerns resurface.

Sector implication: Healthcare's relative performance trajectory depends on policy regime shifts rather than earnings fundamentals. Watch for shifts in inflation expectations and interest rate guidance as leading indicators for XLV's outperformance potential versus the broad market.